CureVac priced its initial public offering at $ 16 per share. The stock grew rapidly more than 200%, to about $ 49. The company that competes with the likes of Modern (MRNA), Novavax (NVAX), BioNTech (BNTX) en Pfizer (PFE), is also supported by billionaire Dietmar Hopp, the co-founder of German …
Read More »Bill and Melinda Gates-backed coronavirus vaccine maker makes debut on Wall Street
